Physician profile
Katelynn K Waldschmidt
NPI 1609379890
$18,262.54
in general payments reported to CMS, 2019-2025
34 companies · $8,031 in 2025
The $8,031 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,963 · 2022: $1,335 · 2023: $2,384 · 2024: $4,550 · 2025: $8,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Honoraria: $2,000 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,350 · Travel and Lodging: $223 · Education: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,244.66 |
| Honoraria | $2,000.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,350.00 |
| Travel and Lodging | $223.16 |
| Education | $147.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,417.15 | 2021-2025 | |
| Qol Medical, LLC | $3,127.23 | 2021-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $2,071.99 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Madrigal Pharmaceuticals | $1,703.74 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $1,208.31 | 2021-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,006.29 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Pfizer INC. | $755.37 | 2021-2025 | |
| Ardelyx, INC. | $633.25 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $468.40 | 2022-2025 | Dupixent |
| Celltrion USA INC. | $442.72 | 2024-2025 | Vegzelma, Zymfentra |
| Evoke Pharma, INC. | $352.53 | 2022-2025 | Gimoti |
| Daiichi Sankyo INC. | $328.21 | 2021-2022 | |
| Celgene Corporation | $320.60 | 2021-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $264.11 | 2021-2024 | Dificid, Zerbaxa, Recarbrio |
| Ironwood Pharmaceuticals, INC | $256.31 | 2021-2025 | Linzess |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $250.65 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $238.50 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $229.64 | 2024-2025 | Iqirvo |
| Redhill Biopharma INC. | $202.88 | 2022-2023 | Talicia, Aemcolo, Movantik |
| Lilly USA, LLC | $195.40 | 2024-2025 | Omvoh |
| Nestle Healthcare Nutrition INC. | $138.21 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $111.77 | 2021-2025 | Ocaliva |
| Aimmune Therapeutics, INC. | $108.64 | 2024-2025 | Zenpep, Vowst |
| Amgen INC. | $87.95 | 2022-2025 | Uplizna, Avsola, Amjevita |
| Fresenius Kabi USA, LLC | $78.93 | 2023-2024 | Idacio |
| Organon LLC | $48.59 | 2022-2024 | Hadlima, Renflexis |
| Astrazeneca Pharmaceuticals LP | $43.88 | 2022-2023 | |
| Ferring Pharmaceuticals INC. | $41.92 | 2022-2025 | Rebyota |
| E.R. Squibb & Sons, L.L.C. | $30.82 | 2023 | Zeposia |
| Medtronic, INC. | $29.64 | 2021-2022 | |
| Gilead Sciences, INC. | $21.71 | 2021 | |
| Enterra Medical, INC. | $18.28 | 2024 | |
| Novo Nordisk INC | $16.53 | 2025 | Wegovy |
| Vivus LLC | $12.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katelynn Waldschmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.